Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1283

1.

Hepatitis C and progression of HIV disease.

Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL.

JAMA. 2002 Jul 10;288(2):199-206.

PMID:
12095384
[PubMed - indexed for MEDLINE]
2.

Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.

Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J; EuroSIDA Study Group.

J Infect Dis. 2005 Sep 15;192(6):992-1002. Epub 2005 Aug 11.

PMID:
16107951
[PubMed - indexed for MEDLINE]
Free Article
3.

Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study.

Hershow RC, O'Driscoll PT, Handelsman E, Pitt J, Hillyer G, Serchuck L, Lu M, Chen KT, Yawetz S, Pacheco S, Davenny K, Adeniyi-Jones S, Thomas DL.

Clin Infect Dis. 2005 Mar 15;40(6):859-67. Epub 2005 Feb 18.

PMID:
15736020
[PubMed - indexed for MEDLINE]
Free Article
4.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group.

Clin Infect Dis. 2005 Jun 15;40(12):e101-9. Epub 2005 May 5.

PMID:
15909251
[PubMed - indexed for MEDLINE]
Free Article
5.

Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects.

De Luca A, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, Poggio A, Pagano G, Tositti G, Cadeo G, Macor A, Toti M, D'Arminio Monforte A; Italian Cohort Naive Antiretrovirals Study Group.

Arch Intern Med. 2002 Oct 14;162(18):2125-32.

PMID:
12374521
[PubMed - indexed for MEDLINE]
6.

Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).

Jaén A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Garcia I, Masabeu A, Altès J, Coltet B, Podzamczer D, Murillas J, Navarro G, Gatell JM, Casabona J; PISCIS Study Group.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):212-20.

PMID:
18297762
[PubMed - indexed for MEDLINE]
7.

Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.

Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT.

AIDS. 2006 May 12;20(8):1171-9.

PMID:
16691069
[PubMed - indexed for MEDLINE]
8.

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.

Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, Montaner JS.

JAMA. 2001 Nov 28;286(20):2568-77.

PMID:
11722271
[PubMed - indexed for MEDLINE]
9.

The influence of HCV coinfection on clinical, immunological and virological responses to HAART in HIV-patients.

Carmo RA, Guimarães MD, Moura AS, Neiva AM, Versiani JB, Lima LV, Freitas LP, Rocha MO.

Braz J Infect Dis. 2008 Jun;12(3):173-9.

PMID:
18833399
[PubMed - indexed for MEDLINE]
Free Article
10.

Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.

Jacobson LP, Li R, Phair J, Margolick JB, Rinaldo CR, Detels R, Muñoz A.

Am J Epidemiol. 2002 Apr 15;155(8):760-70.

PMID:
11943695
[PubMed - indexed for MEDLINE]
Free Article
11.

AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A.

JAMA. 1999 Dec 15;282(23):2220-6.

PMID:
10605973
[PubMed - indexed for MEDLINE]
12.

HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy.

Lincoln D, Petoumenos K, Dore GJ; Australian HIV Observational Database.

HIV Med. 2003 Jul;4(3):241-9.

PMID:
12859323
[PubMed - indexed for MEDLINE]
13.

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.

Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, Burgisser P, Erb P, Boggian K, Piffaretti JC, Hirschel B, Janin P, Francioli P, Flepp M, Telenti A.

Lancet. 2000 Nov 25;356(9244):1800-5. Erratum in: Lancet. 2001 May 12;357(9267):1536.

PMID:
11117912
[PubMed - indexed for MEDLINE]
14.

Impact of chronic hepatitis C infection on outcomes of patients with an advanced stage of HIV-1 infection in an area of low prevalence of co-infection.

Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC.

Int J STD AIDS. 2005 Jan;16(1):42-8.

PMID:
15705272
[PubMed - indexed for MEDLINE]
15.

Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.

Bonnet F, Thiébaut R, Chêne G, Neau D, Pellegrin JL, Mercié P, Beylot J, Dabis F, Salamon R, Morlat P; Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA).

HIV Med. 2005 May;6(3):198-205.

PMID:
15876287
[PubMed - indexed for MEDLINE]
16.

Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.

Braitstein P, Zala C, Yip B, Brinkhof MW, Moore D, Hogg RS, Montaner JS.

J Infect Dis. 2006 Jan 15;193(2):259-68. Epub 2005 Dec 7.

PMID:
16362890
[PubMed - indexed for MEDLINE]
Free Article
17.

Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects.

Chung RT, Evans SR, Yang Y, Theodore D, Valdez H, Clark R, Shikuma C, Nevin T, Sherman KE; AIDS Clinical Trials Group 383 Study Team.

AIDS. 2002 Sep 27;16(14):1915-23.

PMID:
12351951
[PubMed - indexed for MEDLINE]
18.

Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study.

Weis N, Lindhardt BO, Kronborg G, Hansen AB, Laursen AL, Christensen PB, Nielsen H, Moller A, Sorensen HT, Obel N.

Clin Infect Dis. 2006 May 15;42(10):1481-7. Epub 2006 Apr 12.

PMID:
16619163
[PubMed - indexed for MEDLINE]
Free Article
19.

Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.

Torti C, Costarelli S, De Silvestri A, Quiros-Roldan E, Lapadula G, Cologni G, Paraninfo G, Castelnuovo F, Puoti M, Carosi G; BHCC Study Group.

Drug Saf. 2007;30(12):1161-9.

PMID:
18035868
[PubMed - indexed for MEDLINE]
20.

Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients?

Piroth L, Duong M, Quantin C, Abrahamowicz M, Michardiere R, Aho LS, Grappin M, Buisson M, Waldner A, Portier H, Chavanet P.

AIDS. 1998 Mar 5;12(4):381-8.

PMID:
9520167
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk